Randomized Trial of MNrgp120 HIV-1 Vaccine in Symptomless HIV- 1 Infection

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Randomized Trial of MNrgp120 HIV-1 Vaccine in Symptomless HIV- 1 Infection

Lancet (12/07/96) Vol. 348, No. 9041, P. 1547
Eron, Joseph J., Jr.; Ashby, Mark A.; Giordano, Michael F.; et al.

Abstract: Disease progression varies among HIV-infected patients, possibly because of differences in immune response. Previous research has suggested that a vaccine based on the recombinant envelope glycoprotein 120 (rgp 120) may have the potential to elicit antibodies capable of neutralizing HIV-1. Dr. Joseph J. Eron, Jr., of the University of North Carolina's AIDS Clinical Trial Unit, and colleagues, tested an envelope subcomponent vaccine (MNrgp120) in asymptomatic HIV-positive patients to determine if the vaccine could slow disease progression. Among the 573 patients enrolled in the study, 89 percent had detectable HIV RNA at the start. After 15 months, no significant difference in CD4 decline or viral load was found between the vaccine recipients and placebo recipients. The incidence of HIV-related clinical events was also similar for the two groups. The researchers concluded that the vaccine did not affect disease progression in infected individuals.

961217
AD962394

Copyright © 1996 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.